Biogen IDEC Inc. | StockChase
19
Biogen IDEC Inc. (BIIB-Q)

Last Price Recorded: $309.8000 on 2017-11-23

ON STOCKCHASE SINCE May 2004

biotechnology/pharmaceutical

Biogen IDEC Inc.


Signal Opinion Expert

2017-10-02

PARTIAL SELL
Biogen IDEC Inc. (BIIB-Q)

Seasonal strength is from May until the end of September.  It is an opportunity to take some money off the table.

biotechnology/pharmaceutical
Don Vialoux

Research Analyst, TimingTheMarket.CA & EquityClock.COM

Price: $316.170
Owned: Unknown

2017-09-14

DON'T BUY
Biogen IDEC Inc. (BIIB-Q)

It has a large franchise in MS which comprises 75% of their business.  He is seeing potential threat to this franchise from two companies.  Their Alzheimer’ drug comes to trial in 2019 and has high risk.

biotechnology/pharmaceutical
Paul Macdonald

Chief Investment Officer & Portfolio Manager, Harvest Portfolios Group

Price: $323.660
Owned: Unknown

2017-06-28

COMMENT
Biogen IDEC Inc. (BIIB-Q)

US healthcare for the long-term? As opposed to picking just one stock in a sector, your best bet probably is an ETF. If you are looking for an individual stock, one that he holds is Biogen. It is quite cheap relative to its ability to grow earnings.

biotechnology/pharmaceutical
Jason Mann

CIO & Co-Founder, Edgehill Patners

Price: $274.640
Owned: Yes

2017-05-10

COMMENT
Biogen IDEC Inc. (BIIB-Q)

He doesn’t own this because of their concentration in the MS market. There are 2 other companies in this area with possible better drugs. He feels there are going to be very binary outcomes with no dividends. Prefers something with a little more diversity.

biotechnology/pharmaceutical
Paul Macdonald

Chief Investment Officer & Portfolio Manager, Harvest Portfolios Group

Price: $257.920
Owned: No

2017-03-16

TOP PICK
Biogen IDEC Inc. (BIIB-Q)

A bio pharmaceutical. If you look at the traditional Pharma space, the chemical-based companies, the bio-based companies were always out there, coming along, but basically not making a lot of money and were often single drug companies, virtually reinvesting all their cash flow. They have now matured and into much stronger growth companies than the traditional pharmas. They also have lower multiples than they did 5-6 years ago. That makes it quite attractive. (Analysts’ price target is $305.)

biotechnology/pharmaceutical
Gordon Reid

President, GoodReid Investment Counsel

Price: $278.960
Owned: Yes

2016-11-22

HOLD
Biogen IDEC Inc. (BIIB-Q)

(Market Call Minute.) Many people thought the Biotech sector would behave better if Trump got elected. It has had a lift, but it remains to be seen if it can be followed through.

biotechnology/pharmaceutical
David Burrows

President & Chief Investment Strategist, Barometer Capital Management

Price: $318.110
Owned: No

2016-08-15

BUY
Biogen IDEC Inc. (BIIB-Q)

(Market Call Minute.) One of the better growth stories in the US biotech side. They have more of a product portfolio and they have cash. Valuation is in line with the market.

biotechnology/pharmaceutical
John Zechner

Chairman, J. Zechner & Assoc

Price: $313.390
Owned: Unknown

2016-06-22

COMMENT
Biogen IDEC Inc. (BIIB-Q)

Amgen (AMGN-Q), Celgene (CELG-Q) or Biogen (BIIB-Q)? These are 3 great companies. His preference would be Amgen, the leader in the space and the dominant player. This one is a great example of a mega-cap company that has a lot of pent-up interest in one of their phase III’s. Alzheimer’s hasn’t had a great success rate in drug testing, but if it does come positive, you could see some great valuation.

biotechnology/pharmaceutical
Paul Macdonald

Chief Investment Officer & Portfolio Manager, Harvest Portfolios Group

Price: $234.600
Owned: No

2016-03-15

PAST TOP PICK
Biogen IDEC Inc. (BIIB-Q)

(A Top Pick March 10/15. Down 39.56%.) For about 3 years Biotech was one of the leading groups in the market. He stays in positions as long as they work, and runs Stop Losses. In July, biotech as a group rolled over and he got stopped out at about $308-$310.

biotechnology/pharmaceutical
David Burrows

President & Chief Investment Strategist, Barometer Capital Management

Price: $250.330
Owned: No

2016-02-18

PAST TOP PICK
Biogen IDEC Inc. (BIIB-Q)

(Top Pick Mar 10/15, Down 36.01%)  He got stopped out last March.  They missed a number.  He is not buying biotech right now.

biotechnology/pharmaceutical
David Burrows

President & Chief Investment Strategist, Barometer Capital Management

Price: $259.050
Owned: No

2015-07-22

BUY on WEAKNESS
Biogen IDEC Inc. (BIIB-Q)

Has been watching this for a little while. It doesn’t trade at an extreme valuation and they have a nice pipeline. A drug that propelled them recently was their new Alzheimer’s one that is still in testing. A very promising drug. In a short time they are going to come out with the results of a new test on it. He thinks the market will react on this, so he would be hesitant to buy in front of that. If you can buy this in the $350-$375 area, it has a lot of promise.

biotechnology/pharmaceutical
Gordon Reid

President, GoodReid Investment Counsel

Price: $391.740
Owned: No

2015-04-30

COMMENT
Biogen IDEC Inc. (BIIB-Q)

This is in the right space to him. It is in a sector that he thinks is going to change humanity in a way the PC changed things in 1982, the way the baby boomers did it coming back from the war, or the 2nd Industrial Revolution. These are large secular pictures that really moved society. They happen in such a way that you actually don’t see the occurrences while you’re in them. If you don’t want to look at this one in particular, you can look at any of the biotech related ETF’s. He doesn’t own any of these, but is waiting with bated breath for an opportunity to do that.

biotechnology/pharmaceutical
Hap (Robert) Sneddon FCSI

Chief Portfolio Manager & Founder, Castlemoore Inc.

Price: $373.930
Owned: No

2015-03-10

TOP PICK
Biogen IDEC Inc. (BIIB-Q)

You have an aging population in the US that is relatively insensitive to price. Last year pharmaceutical prices rose 13%. This company has the dominant market share position in neurological drugs for things such as multiple sclerosis and Alzheimer’s. They have some very important trials in March on Alzheimer’s, which are potentially blockbuster findings. They may either slow down the onset or, more importantly, actually show some reversing. As the Affordable Care act comes in, there are more people that have money to spend on healthcare. In the next couple of years there are lots of additional trials that will come.

biotechnology/pharmaceutical
David Burrows

President & Chief Investment Strategist, Barometer Capital Management

Price: $414.200
Owned: Yes

2014-04-22

WAIT
Biogen IDEC Inc. (BIIB-Q)

The period of seasonal strength comes predominately during the summertime, from August through until October. The average gain from July through to October is about 30% on an annual basis. The strongest month is July, so if you can take a position before July, it will give you added value. Currently this is trying to find a bottom. It is bouncing off of oversold levels. Doesn’t expect you would find the bottom at this point. Wait until the summer.

biotechnology/pharmaceutical
Jon Vialoux

Research Analyst, Timingthemarket.ca & Equityclock.com

Price: $306.200
Owned: Unknown

2014-01-14

DON'T BUY
Biogen IDEC Inc. (BIIB-Q)

(Market Call Minute.) Closed at $283.67 and his model price is $180, a 36% negative. Too expensive here.

biotechnology/pharmaceutical
Brian Acker, CA

Chief Executive Officer, President and Chief Inves, Acker Finley Inc.

Price: $297.470
Owned: Unknown

Showing 1 to 15 of 19 entries
<< < 1 2 > >>

No Comments.


You must be logged in to comment.